Ropes & Gray advised Sanofi on the deal. Sanofi announced a strategic equity investment in Torino, Italy-based Resalis Therapeutics (Resalis Therapeutics). The company plans to use...
You must be a Standard 1 Year member to access this content.
Vinge advised Vicore Pharma Holding AB on the deal, and Ropes & Gray advised Sanofi. Vicore Pharma Holding AB (publ) secured a directed share issue, whereby...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Sanofi in the transaction, and Wilson Sonsini Goodrich & Rosati represented Ventyx Biosciences, Inc. Sanofi announced a $27 million strategic investment in...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised FogPharma on the transaction. FogPharma announced a collaboration with ARTBIO Inc. to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray is advising BPEA EQT, and Latham & Watkins is advising Endeavor. EQT announced that BPEA Private Equity Fund VIII (an affiliated investment fund of...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised IDRx on the deal. Clinical stage precision cancer biopharmaceutical company IDRx announced licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to...
You must be a Standard 1 Year member to access this content.
